Pfizer (PFE) traded down -0.8 % during a 24 hours period ending at 01:06 PM Central Europe on Tuesday 27th. One Pfizer stock can currently be bought for about USD 29.79 on popular exchanges. Current supply of Pfizer stocks is 5.7 bn. Pfizer has a current market capitalization of USD 172.1 bn and approximately USD 763.6 mn worth of Pfizer was traded on exchanges in the last 24 hours. Since last month end, Pfizer has traded 3.73 % up. Simple moving average of last 200 days is at USD 26.71. The highest price of past 52 weeks was recorded at USD 30.44 on 10/22/2026. 52 weeks low was at USD 23.62 on 07/06/2026.
Summary of the latest news for Pfizer
Pfizer announced that the U.S. Food and Drug Administration has expanded approval of its Talzenna‑plus Xtandi combination for men with metastatic hormone‑sensitive prostate cancer carrying homologous‑recombination‑repair gene mutations. The expansion follows a phase‑3 study that demonstrated a substantial reduction in the risk of disease progression or death compared with standard therapy, and the company reported no new safety signals. The approval extends the use of the combination earlier in the disease course, offering a new therapeutic option for patients who remain sensitive to androgen deprivation.
Here is how related stocks have performed in the past 24 hours:
Sandisk (SNDK) traded up 1.42 % and now trades at USD 1,255.58. Sandisk has a market capitalisation of USD 184.6 bn. Current price/earnings ratio for Sandisk is 16.94.
Marvell (MRVL) traded up 2.31 % and now trades at USD 233.78. Current market capitalisation for Marvell is USD 201.6 bn. Current price/earnings ratio for Marvell is 76.91.
Salesforce (CRM) traded down -0.39 % and now trades at USD 247.61. Salesforce has a market capitalisation of USD 205.5 bn. Salesforce has a current price to earnings ratio of 23. Salesforce announced a new debt offering to support its cloud infrastructure expansion, following a recent increase in capital spending on artificial‑intelligence and data‑center development. The company said the issuance will fund a significant share‑buyback programme and an ongoing dividend uplift, while reinforcing its long‑term growth strategy. The debt is part of a broader shift among technology firms toward external financing to accelerate AI and cloud initiatives. The announcement aligns with Salesforce’s recent record‑high capital deployment and reflects its commitment to sustaining investment momentum in core cloud services.
Qualcomm (QCOM) traded up 2.1 % and now trades at USD 179.6. Qualcomm has a market capitalisation of USD 189.3 bn. Current price/earnings ratio for Qualcomm is 20.48. Qualcomm Inc. reported a stable earnings outlook for the first half of the year, with guidance that the company expects its revenue to remain broadly in line with prior forecasts and its profit margins to hold steady. The company also reiterated its focus on expanding its portfolio of advanced chip technologies, noting continued investment in research and development for next‑generation processors and system‑on‑chip solutions. While the company’s share price showed modest volatility during the trading session, no significant change was announced in its dividend policy or capital‑structure strategy. No material regulatory filings or strategic initiatives beyond its existing roadmap were disclosed in the latest update.
Gilead Sciences (GILD) traded up 1.7 % and now trades at USD 158.69. Current market capitalisation for Gilead Sciences is USD 196.3 bn. Gilead Sciences has announced a collaboration with Innovaccer to extend the reach of its oncology data platform. The partnership aims to integrate Gilead’s real‑world evidence into Innovaccer’s AI‑driven analytics, enhancing insights for cancer treatment development. No financial terms were disclosed. The move follows Gilead’s recent focus on data‑driven oncology solutions, complementing its existing drug portfolio and supporting its broader strategy to leverage digital tools for patient outcomes. No immediate impact on share price has been reported.
About Pfizer
Pfizer Inc., a pharmaceutical company based in New York, offers a diverse range of products and services for various therapeutic areas including oncology, inflammation, cardiovascular issues, and more. The company serves customers globally and can be accessed online through their website at www.pfizer.com . Pfizer is listed on the New York Stock Exchange.
